Inhibition of xanthine oxidase and exercise on serum uric acid, 25(OH)D3, and calcium concentrations
BACKGROUND: It has been shown that serum concentrations of 1,25(OH)2D3 are decreased in patients with gout. A short-term administration of allopurinol increases plasma concentrations of 1,25(OH)2D3 in mild to moderate renal failure, with or without hyperuricemia. It has been reported that subjects who perform regular vigorous and/ or moderate physical activities have higher plasma and serum 25(OH)D3 levels. However, little is known about the influence of allopurinol and/or physical exercise on serum 25(OH)D3 concentrations in humans.
METHODS: We investigated the effect of allopurinol administration and/or physical activity on vitamin D metabolism by measuring serum uric acid, 25(OH)D3, and calcium levels in twelve professional soccer players.
RESULTS: The athletes supplemented with allopurinol, but not those who received placebo, exhibited a significant decrease in uric acid serum concentrations after the match. We also found a significant increase in serum calcium and 25(OH)D3 concentrations in the supplemented group.
CONCLUSIONS: We conclude that allopurinol administration might be an effective drug to lower hyperuricemia and treat hypovitaminosis D.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Clinical laboratory - 60(2014), 8 vom: 09., Seite 1409-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanchis-Gomar, Fabian [VerfasserIn] |
|---|
| Themen: |
268B43MJ25 |
|---|
| Anmerkungen: |
Date Completed 06.10.2014 Date Revised 10.03.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM241560888 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM241560888 | ||
| 003 | DE-627 | ||
| 005 | 20231224124525.0 | ||
| 007 | tu | ||
| 008 | 231224s2014 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0805.xml |
| 035 | |a (DE-627)NLM241560888 | ||
| 035 | |a (NLM)25185430 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanchis-Gomar, Fabian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibition of xanthine oxidase and exercise on serum uric acid, 25(OH)D3, and calcium concentrations |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 06.10.2014 | ||
| 500 | |a Date Revised 10.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: It has been shown that serum concentrations of 1,25(OH)2D3 are decreased in patients with gout. A short-term administration of allopurinol increases plasma concentrations of 1,25(OH)2D3 in mild to moderate renal failure, with or without hyperuricemia. It has been reported that subjects who perform regular vigorous and/ or moderate physical activities have higher plasma and serum 25(OH)D3 levels. However, little is known about the influence of allopurinol and/or physical exercise on serum 25(OH)D3 concentrations in humans | ||
| 520 | |a METHODS: We investigated the effect of allopurinol administration and/or physical activity on vitamin D metabolism by measuring serum uric acid, 25(OH)D3, and calcium levels in twelve professional soccer players | ||
| 520 | |a RESULTS: The athletes supplemented with allopurinol, but not those who received placebo, exhibited a significant decrease in uric acid serum concentrations after the match. We also found a significant increase in serum calcium and 25(OH)D3 concentrations in the supplemented group | ||
| 520 | |a CONCLUSIONS: We conclude that allopurinol administration might be an effective drug to lower hyperuricemia and treat hypovitaminosis D | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 650 | 7 | |a Allopurinol |2 NLM | |
| 650 | 7 | |a 63CZ7GJN5I |2 NLM | |
| 650 | 7 | |a Cellulose |2 NLM | |
| 650 | 7 | |a 9004-34-6 |2 NLM | |
| 650 | 7 | |a Xanthine Oxidase |2 NLM | |
| 650 | 7 | |a EC 1.17.3.2 |2 NLM | |
| 650 | 7 | |a Calcifediol |2 NLM | |
| 650 | 7 | |a P6YZ13C99Q |2 NLM | |
| 650 | 7 | |a Calcium |2 NLM | |
| 650 | 7 | |a SY7Q814VUP |2 NLM | |
| 700 | 1 | |a Salvagno, Gian Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical laboratory |d 1998 |g 60(2014), 8 vom: 09., Seite 1409-11 |w (DE-627)NLM096449845 |x 1433-6510 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2014 |g number:8 |g day:09 |g pages:1409-11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2014 |e 8 |b 09 |h 1409-11 | ||